(Q33840177)

29 July 2017

1 reference

title

Well-differentiated neuroendocrine tumors: a review covering basic principles to loco-regional and targeted therapies (English)

1 reference

29 July 2017

C Schmidt

1

1 reference

29 July 2017

M Bloomston

series ordinal

2

1 reference

29 July 2017

M H Shah

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

6 December 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

30

1 reference

29 July 2017

issue

13

1 reference

29 July 2017

page(s)

1497-1505

1 reference

90Y-edotreotide for metastatic carcinoid refractory to octreotide

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Biochemical testing for neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Activity of sunitinib in patients with advanced neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Clinical and in vitro studies of imatinib in advanced carcinoid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Current status of gastrointestinal carcinoids

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Serum peptide profiles in patients with carcinoid tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4080204

Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies

5 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Chemoembolization in patients at high risk: results and complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

A phase II study of docetaxel in patients with metastatic carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Indium-111–Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Hepatic resection for metastatic neuroendocrine carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Neuroendocrine hepatic metastases: does aggressive management improve survival?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Repeat transarterial chemoembolization (TACE) for progressive hepatic carcinoid metastases provides results similar to first TACE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.548

Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21132004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A single-centre experience with octreotide in the treatment of different hypersecretory syndromes in patients with functional gastroenteropancreatic neuroendocrine tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21132004

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2010.548

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference